Fundraising Fox
🦊/Companies
Sign in

Intus Biosciences

Farmington, US · Founded 2014 · Connecticut LLC · 1 known investors

Find your way into Intus Biosciences

1,473 people in our graph share verified history with the Intus Biosciences team — schools, employers, funds. One of them is your warm intro.

Ottounlockedknows Daniel Fasulo · together at Siemens (overlapped)
knows the team · via HSBC
knows the team · via University of Washington
×3knows the team · via Colgate University
×3knows the team · via University of Bath
knows the team · via Standard Chartered Bank

Intus Bio develops Titan-1, a microbiome analysis technology that combines long-read sequencing, patented science, and AI to produce higher-resolution microbiome data than shotgun metagenomic and 16S approaches. It applies these insights to biomarker discovery, drug development, and patient testing across healthcare.

AI & Machine LearningBiotechDigital Health

Founders & leadership

Intus Biosciences was founded in 2014 by Thomas P Jarvie and Mark Driscoll.

TPThomas P Jarvie
Thomas P JarvieinCEO and Co-Founder2021–2021
MDMark Driscoll
Mark DriscollinCSO & Co-Founder
PDPaul Denslow
Paul DenslowinCEO & Co-FounderPaul Denslow is CEO and co-founder of Intus Biosciences, which develops microbiome analysis technology combining sequencing and AI for diagnostic and drug discovery applications.
DFDaniel Fasulo
Daniel FasuloinHead of Bioinformatics & ITHe was a foundational member of the Celera team that assembled the first human genome and has over 25 years of experience in bioinformatics algorithm development, with expertise in AI/ML applications, high-performance software engineering, and genomics; he holds multiple patents and has published in Science and PNAS.
PLPeter Lee
Peter LeeinHead of Corporate StrategyPeter Lee serves as Head of Corporate Strategy at Intus Biosciences. He previously held senior management roles in biotechnology and information technology companies, overseeing functions including legal, government relations, human resources, marketing, communications, and operations.

Investors · 1

Connecticut InnovationsNew Haven · $500K – $2M

Reported raises · per SEC filings

Form D private placements

$10.1M disclosed across 10 rounds · 2016–2025

▶$1.1MraisedMay 2025 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Donna GalluzzoDirector
  • Paul DenslowExecutive Officer, Director
  • Frank J. MarcoDirector
  • Alan MendelsonDirector
  • Daniel WagnerDirector
  • Mark DriscollDirector
Offering amount
$3M
Amount sold
$1.1M
First sale
May 2025
Incorporated
Limited Liability Company, Connecticut
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedJul 2024 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul DenslowExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
First sale
Jun 2024
Incorporated
Limited Liability Company, Connecticut
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedNov 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas JarvieExecutive Officer, Director
  • Paul DenslowExecutive Officer, Director
  • Alan MendelsonDirector
  • Matt WatsonDirector
  • Frank J. MarcoDirector
Offering amount
$3.5M
Amount sold
$1.1M
First sale
Nov 2022
Incorporated
Limited Liability Company, Connecticut
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$800KraisedJul 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William McKenzieDirector
  • H. Mark LunenburgDirector
  • David WurzerDirector
  • Paul DenslowExecutive Officer, Director
  • Alan MendelsonDirector
  • Thomas JarvieExecutive Officer, Director
  • Frank J. MarcoDirector
Offering amount
$1.5M
Amount sold
$800K
First sale
Jun 2022
Incorporated
Limited Liability Company, Connecticut
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$250KraisedFeb 2022 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William McKenzieDirector
  • H. Mark LunenburgDirector
  • David WurzerDirector
  • Thomas JarvieExecutive Officer, Director
  • Paul DenslowDirector
  • Frank MarcoDirector
Offering amount
$250K
Amount sold
$250K
First sale
Jan 2022
Incorporated
Limited Liability Company, Connecticut
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$330KraisedJan 2021 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas JarvieExecutive Officer, Director
  • William McKenzieDirector
  • Frank MarcoDirector
  • Patrick O'NeillDirector
  • H. Mark LunenburgDirector
Offering amount
$1M
Amount sold
$330K
First sale
Dec 2020
Incorporated
Limited Liability Company, Connecticut
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedMay 2020 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas JarvieExecutive Officer, Director
  • William McKenzieDirector
  • Patrick O'NeillDirector
  • Frank MarcoDirector
  • H. Mark LunenburgDirector
Offering amount
$2.2M
Amount sold
$2.2M
First sale
May 2019
Incorporated
Limited Liability Company, Connecticut
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedDec 2017 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Frank J. MarcoDirector
  • Mark D. DriscollExecutive Officer, Director
  • Patrick O'NeillDirector
  • Thomas P. JarvieExecutive Officer, Director
Offering amount
$1.9M
Amount sold
$1.8M
First sale
Dec 2017
Incorporated
Limited Liability Company, Connecticut, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 6

by search overlap
Hurdle4 shared keywordsHurdle provides diagnostic testing infrastructure for healthcare partners, including sample collection kits, lab network access, fulfillment services, and biomarker R&D capabilities across the UK and EU.
Tiny Health4 shared keywordsTiny Health offers at-home gut and vaginal microbiome test kits with age-specific, evidence-based reports that recommend diet, supplement, and lifestyle changes. It targets families across life stages—from preconception and pregnancy through infancy, childhood, and adulthood—to detect microbiome imbalances and support prevention of conditions like eczema, allergies, and GI issues.
Rupa Health4 shared keywordsA platform that enables healthcare providers to order, track, and receive lab test results from multiple laboratory companies through a single dashboard, supporting both in-person and telehealth patients with flexible billing options and EHR integration.
Pacb4 shared keywordsPacific Biosciences manufactures consumables and reagent kits for long-read DNA and RNA sequencing platforms, serving genomics research and diagnostics labs.
Viome4 shared keywordsViome offers at-home tests that analyze the gut and oral microbiome plus cellular blood samples using mRNA/metatranscriptomic sequencing, returning 70+ health scores (including biological age and inflammation) and personalized food and supplement recommendations. The direct-to-consumer service, analyzed in a CLIA-certified lab, is aimed at individuals seeking insights into digestion, metabolism, and overall wellness.
BIOHM3 shared keywordsBIOHM sells probiotic supplements and at-home gut test kits that analyze the microbiome, with results reviewed by a microbiome-trained registered nutritionist who provides personalized diet and supplement recommendations. Its formula combines bacteria, fungi, and a digestive enzyme intended to support digestive health.

Companies competing with Intus Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Intus Biosciences do?
Intus Bio develops Titan-1, a microbiome analysis technology that combines long-read sequencing, patented science, and AI to produce higher-resolution microbiome data than shotgun metagenomic and 16S approaches. It applies these insights to biomarker discovery, drug development, and patient testing across healthcare.
Who founded Intus Biosciences?
Intus Biosciences was founded by Thomas P Jarvie, Mark Driscoll in 2014.
Who are Intus Biosciences's investors?
Intus Biosciences's investors include Connecticut Innovations.
How much funding has Intus Biosciences raised?
Intus Biosciences has disclosed $10.1M raised across 10 rounds.
Where is Intus Biosciences headquartered?
Intus Biosciences is headquartered in Farmington, US.